Recently, the FDA has approved osimertinib (Tagrisso) or AZD9291, a third-generation EGFR TKI, as a breakthrough treatment for NSCLC patients whose tumors have a T790M mutation and whose disease has worsened after treatment with other EGFR inhibitors. Here, EGFR is linked to non-small cell lung carcinoma.